The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 14, Issue 4, 2011, Pages 347-353

  Martínez Clemente, Marcos ^a   Clària, Joan ^a,b,c   Titos, Esther ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

5 lipoxygenase; adipose tissue; inflammation; leukotrienes; metabolic syndrome

Indexed keywords

AM 103; ANTIINFLAMMATORY AGENT; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; BLT1 RECEPTOR; BLT2 RECEPTOR; DG 051; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LEUKOTRIENE; LEUKOTRIENE B4 RECEPTOR; LICOFELONE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONTELUKAST; OXYGENASE INHIBITOR; PRANLUKAST; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZAFIRLUKAST; ZILEUTON;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATHEROSCLEROSIS; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OSTEOARTHRITIS; PATHOGENESIS; PROTEIN PROTEIN INTERACTION; RESPIRATORY TRACT DISEASE; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; ARACHIDONATE 5-LIPOXYGENASE; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; FATTY LIVER; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; LEUKOTRIENES; MACROPHAGE INFLAMMATORY PROTEINS; METABOLIC SYNDROME X; NF-KAPPA B; OBESITY; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959227567     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32834777fa     Document Type: Review

References (47)

1. Samuelsson B, Dahlen SE, Lindgren JA, et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237:1171-1176. (Pubitemid 17131222)
2. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294:1871-1875. (Pubitemid 33101574)
3. Romano M, Clà ria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003; 17:1986-1995. (Pubitemid 37392443)
4. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual antiinflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8:349-361. (Pubitemid 351595216)
5. Newcomer ME, Gilbert NC. Location, location, location: compartmentalization of early events in leukotriene biosynthesis. J Biol Chem 2010; 285:25109-25114.
6. Boudreau LH, Bertin J, Robichaud PP, et al. Novel 5-lipoxygenase isoforms affect the biosynthesis of 5-lipoxygenase products. FASEB J 2011; 25: 1097-1105.
7. Gilbert NC, Bartlett SG, Waight MT, et al. The structure of human 5-lipoxygenase. Science 2011; 331:217-219.
8. Haeggström JZ, Rinaldo-Matthis A, Wheelock CE, Wetterholm A. Advances in eicosanoid research, novel therapeutic implications. Biochem Biophys Res Commun 2010; 396:135-139.
9. Iizuka Y, Okuno T, Saeki K, et al. Protective role of the leukotriene B4 receptor BLT2 in murine inflammatory colitis. FASEB J 2010; 24:4678-4690.
10. Cho KJ, Seo JM, Lee MG, Kim JH. BLT2 is upregulated in allergen-stimulated mast cells and mediates the synthesis of Th2 cytokines. J Immunol 2010; 185:6329-6337.
11. González-Périz A, Clària J. New approaches to the modulation of the cyclooxygenase-.2. and 5-lipoxygenase pathways. Curr Top Med Chem 2007; 7:297-309. (Pubitemid 46358663)
12. Riccioni G, Bucciarelli T, Mancini B, et al. Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem 2007; 14:1966-1977. (Pubitemid 47209107)
13. Bain G, King CD, Rewolinski M, et al. Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP). Clin Pharmacol Ther 2010; 87:437-444.
14. Sandanayaka V, Mamat B, Mishra RK, et al. Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. J Med Chem 2010; 53:573-585.
15. Raynauld JP, Martel-Pelletier J, Bias P, et al. Protective effects of licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, versus naxopren on cartilage loss in knee osteoarthritis: a first multicentre clinic trial using quantitative MRI. Ann Rheum Dis 2009; 68:938-947.
16. FunkCD, Chen XS, Johnson EN, Zhao L. Lipoxygenase genes and their targeted disruption. Prostaglandins Other Lipid Mediat 2002; 68-69:303-312. (Pubitemid 35247403)
17. Chen M, Lam BK, Luster AD, et al. Joint tissues amplify inflammation and alter their invasive behavior via leukotriene B4 in experimental inflammatory arthritis. J Immunol 2010; 185:5503-5511.
18. Zhao L, Moos MP, Grä bner R, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 2004; 10:966-973. (Pubitemid 39273738)
19. Cao RY, St Amand T, Gräbner R, et al. Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice. Atherosclerosis 2009; 203:395-400.
20. Chen Y, Hu Y, Zhang H, et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 2009; 41:783-792.
21. Byrum RS, Goulet JL, Griffiths RJ, Koller BH. Role of the 5-lipoxygenaseactivating protein (FLAP) in murine acute inflammatory responses. J Exp Med 1997; 185:1065-1075. (Pubitemid 27136799)
22. Snelgrove RJ, Jackson PL, Hardison MT, et al. A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science 2010; 330: 90-94.
23. Mathis SP, Jala VR, Lee DM, Haribabu B. Nonredundant roles for leukotriene B4 receptors BLT1 and BLT2 in inflammatory arthritis. J Immunol 2010; 185:3049-3056.
24. Ivanov I, Heydeck D, Hofheinz K, et al. Molecular enzymology of lipoxygenases. Arch Biochem Biophys 2010; 503:161-174.
25. Chakrabarti SK, Cole BK, Wen Y, et al. 12/15-lipoxygenase products induce inflammation and impair insulin signaling in 3T3-L1 adipocytes. Obesity 2009; 17:1657-1663.
26. Wen Y, Gu J, Liu Y, et al. Overexpression of 12-lipoxygenase causes cardiac fibroblast cell growth. Circ Res 2001; 88:70-76. (Pubitemid 32064085)
27. Natarajan R, Rosdahl J, Gonzales N, Bai W. Regulation of 12-lipoxygenase by cytokines in vascular smooth muscle cells. Hypertension 1997; 30:873-879. (Pubitemid 27441116)
28. Kayama Y, Minamino T, Toko H, et al. Cardiac 12/15 lipoxygenase-induced inflammation is involved in heart failure. J Exp Med 2009; 206:1565-1574.
29. Prasad KM, Thimmalapura PR, Woode EA, Nadler JL. Evidence that increased 12-lipoxygenase expression impairs pancreatic beta-cell function and viability. Biochem Biophys Res Commun 2003; 308:427-432. (Pubitemid 36945508)
30. Cyrus T, PraticòD, Zhao L, et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice. Circulation 2001; 103:2277-2282. (Pubitemid 32433718)
31. Elks CM, Francis J. Central adiposity, systemic inflammation, and the metabolic syndrome. Curr Hypertens Rep 2010; 12:99-104.
32. Ferrante AW Jr. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med 2007; 262:408-414. (Pubitemid 47404372)
33. Donnelly KI, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted with lipoproteins in patients with nonalcoholic fatty liver diseases. J Clin Invest 2005; 115:1343-1351. (Pubitemid 40629054)
34. Law K, Brunt EM. Nonalcoholic fatty liver disease. Clin Liver Dis 2010; 14:591-604.
35. Kaaman M, Rydén M, Axelsson T, et al. ALOX5AP expression, but not gene haplotypes, is associated with obesity and insulin resistance. Int J Obes 2006; 30:447-452.
36. Horrillo R, González-Périz A, Martínez-Clemente M, et al. 5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J Immunol 2010; 184:3978-3987.
37. Mehrabian M, Schulthess FT, Nebohacova M, et al. Identification of ALOX5 as a gene regulating adiposity and pancreatic function. Diabetologia 2008; 51:978-988.
38. Chakrabarti SK, Wen Y, Dobrian AD, et al. Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats. Am J Physiol Endocrinol Metab 2011; 300:E175-E187.
39. Gowri MS, Azhar RK, Kraemer FB, et al. Masoprocol decreases rat lipolytic activity by decreasing the phosphorylation of HSL. Am J Physiol Endocrinol Metab 2000; 279:E593-E600.
40. Nunemaker CS, Chen M, Pei H, et al. 12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by Western diet. Am J Physiol 2008; 295:1065-1075.
41. Sears DD, Miles PD, Chapman J, et al. 12/15-lipoxygenase is required for the early onset of high fat diet-induced adipose tissue inflammation and insulin resistance in mice. PLoS One 2009; 4:e7250.
42. Dobrian AD, Lieb DC, Ma Q, et al. Differential expression and localization of 12/15 lipoxygenases in adipose tissue in human obese subjects. Biochem Biophys Res Commun 2010; 403:485-490.
43. FerréN, Martínez-Clemente M, López-Parra M, et al. Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. Am J Physiol Gastrointest Liver Physiol 2009; 296:G553-G562.
44. Martínez-Clemente M, FerréN, González-Périz A, et al. 5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. Hepatology 2010; 51:817-827.
45. Martínez-Clemente M, FerréN, Titos E, et al. Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease. Hepatology 2010; 52:1980-1991.
46. Puri P, Wiest MM, Cheung O, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009; 50:1827-1838.
47. Titos E, FerréN, Lozano JJ, et al. Protection from hepatic lipid accumulation and inflammation by genetic ablation of 5-lipoxygenase. Prostaglandins Other Lipid Mediat 2010; 92:54-61.